NASDAQ: ICCC - ImmuCell Corporation

Rentabilité sur six mois: +40.24%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions ImmuCell Corporation

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise ImmuCell Corporation

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.

plus de détails
The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 1987-04-30
ISIN US4525253062
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://immucell.com
Цена ао 5.48
Changement de prix par jour: -1.31% (5.35)
Changement de prix par semaine: +5.18% (5.02)
Changement de prix par mois: -2.22% (5.4)
Changement de prix sur 3 mois: +28.16% (4.12)
Changement de prix sur six mois: +40.24% (3.765)
Changement de prix par an: 0% (5.28)
Evolution du prix sur 3 ans: -36.61% (8.33)
Evolution du prix sur 5 ans: -1.49% (5.36)
Evolution des prix sur 10 ans: 0% (5.28)
Evolution des prix depuis le début de l'année: +14.53% (4.61)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 2.08 7
P/BV 1.45 9
P/E 0 0
EV/EBITDA -17.15 0
Total: 5.5

Efficacité

Nom Signification Grade
ROA, % -13.18 0
ROE, % -23.1 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -5.51 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 27.53 4
Rentabilité Ebitda, % 162.48 10
Rentabilité EPS, % 292.07 10
Total: 8.8
Plus de détails

Établissements Volume Partager, %
Vanguard Group Inc 206606 2.67
Renaissance Technologies, LLC 126189 1.63
Cresset Asset Management, LLC 103606 1.34
Bleichroeder LP 101594 1.31
Morgan Stanley 84574 1.09
Shufro, Rose & Co., LLC 62408 0.81
Dimensional Fund Advisors LP 57451 0.74
Geode Capital Management, LLC 53213 0.69
Susquehanna International Group, LLP 33720 0.44
Overbrook Management Corp 32857 0.42

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
iShares Micro-Cap ETF 0.00524 17.09 1.54048
Dimensional U.S. Targeted Value ETF 0.00039 26.01 1.93487
Dimensional U.S. Core Equity 2 ETF 0 30.76 1.47098



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Michael F. Brigham President, CEO, Principal Financial Officer, Treasurer, Secretary & Director 395.24k 1961 (64 année)
Ms. Bobbi Jo Brockmann VP of Sales & Marketing and Director 323.52k 1977 (48 années)
Mr. A. Gustavo Scaffa Senior Director of Quality N/A
John W. Zinckgraf Director of Product Development N/A
Ms. Elizabeth L. Williams Vice President of Manufacturing Operations 312.07k 1956 (69 années)
Ms. Elizabeth S. Toothaker Director of Finance & Administration and Controller N/A

Adresse: United States, Portland. ME, 56 Evergreen Drive - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://immucell.com